Retrospective Cohort Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2016; 7(3): 283-287
Published online Aug 15, 2016. doi: 10.4291/wjgp.v7.i3.283
“Magic” of our gastric cancer results on perioperative chemotherapy
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano, Department of Digestive and General Surgery, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
Author contributions: All authors contributed equally to this work.
Institutional review board statement: Institutional Review Board’s approval is unnecessary for this manuscript, because of its retrospective character. Individual subjects cannot be identified in any way by the data collected.
Informed consent statement: Informed consent is unnecessary for this manuscript, because of its retrospective character. Individual subjects cannot be identified in any way by the data collected.
Conflict-of-interest statement: All authors declare having no conflicts of interest of any kind.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at garalma@hotmail.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marina Garces-Albir, MD, PhD, Department of Digestive and General Surgery, Hospital Clínico Universitario de Valencia, Avd. Blasco Ibañez, 17, 46010 Valencia, Spain. garalma@hotmail.com
Telephone: +34-96-2051717 Fax: +34-96-3868864
Received: March 22, 2016
Peer-review started: March 23, 2016
First decision: April 15, 2016
Revised: April 28, 2016
Accepted: May 17, 2016
Article in press: May 27, 2016
Published online: August 15, 2016
Abstract

AIM: To determine reproducibility of perioperative chemotherapy for gastric cancer (GC) on our settings by identifying patient’s overall survival and comparing them to larger studies.

METHODS: Retrospective analysis of our series, where we present our eleven-year’s experience on GC managed according to perioperative approach of three preoperative chemotherapy cycles followed by surgery and finally three postoperative chemotherapy cycles. Chemotherapic scheme used was Xelox (Oxaliplatin and Capecitabine). Epidemiologic parameters as well as surgical variables were analysed, presented, and compared to other series with similar approaches. Survival was estimated by Kaplan Meier/log rank method and also compared to these studies.

RESULTS: Mean age was 65 years old. Overall survival in our series was 37.7%, similar to other groups using perioperative schemes. Mortality was 4% and morbidity 30%, which are also similar to those groups. Survival curves were compared to larger studies, finding similarities on them. Subgroup survival analysis between chemotherapy responders and non-responders didn’t reach statically significant differences.

CONCLUSION: Perioperative chemotherapic scheme can be reproduced on our setting with good results and without increasing morbidity or mortality.

Keywords: Stomach neoplasms, Perioperative period, Chemotherapy

Core tip: This is a retrospective study that evaluates and compares survival after perioperative chemotherapy on gastric cancer patients managed similarly in other settings. We confirmed reproducibility of this scheme on smaller settings than classic studies.